PHILADELPHIA — Years after a single traumatic brain injury (TBI), survivors still show changes in their brains. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania suggest that Alzheimer's disease-like neurodegeneration may be initiated or accelerated following a single traumatic brain injury, even in young adults.
Over 1.7 million Americans suffer a traumatic brain injury each year, and beyond the immediate effects, growing evidence demonstrates that a single TBI may initiate long-term processes that further damage the brain. TBI is an established risk factor for later development of cognitive impairments, such as Alzheimer's disease.
"A single traumatic brain injury is very serious, both initially, and as we're now learning, even later in life," said Douglas Smith, MD, professor of Neurosurgery and director of the Center for Brain Injury and Repair at Penn's Perelman School of Medicine, the study's co-senior author. "Plaques and tangles are appearing abnormally early in life, apparently initiated or accelerated by a single TBI."
The study appears online in Brain Pathology, and was done in conjunction with neuropathologist Dr. William Stewart, from the University of Glasgow and Southern General Hospital in Glasgow, UK.
The researchers found both tau tangles and amyloid-beta plaques in survivors, years after a single moderate-to-severe TBI. In repetitive head injury, previous studies have shown a tau accumulation as the signature pathology of a condition called chronic traumatic encephalopathy. In studies of people less than 4 weeks after dying from a single TBI, no similar tau pathology was found. In addition, while widespread amyloid-beta plaques have been found in about 30 percent of people shortly after injury, previous work showed that plaques disappeared within months.
In this study, researchers examined post-mortem brains from 39 long-term survivors of a single TBI, extending the survival time from 1-47 years survival after TBI, and compared them to uninjured, age-matched controls.
TBI survivors showed a high density and wide distribution of neurofibrillary tau tangles and amyloid-beta plaque pathology far beyond what was found in controls. Specifically, about a third of the cases showed tangle pathology years after a single TBI, similar in appearance to the tangles found after repetitive TBI and in neurodegenerative diseases such as Alzheimer's disease. Moreover, the amyloid-beta plaques were not only found years after TBI, but the majority of cases displayed diffuse as well as "neuritic" plaques with the same character as "senile" plaques also found in Alzheimer's disease. This suggests that years after a single TBI, amyloid-beta plaques may return and become neuritic.
The present findings, showing that two hallmark pathologies of Alzheimer's disease can be found years after a single TBI, may provide a pathological link with the epidemiological observation of an increased risk of developing Alzheimer's disease. Moreover, future research to better understand this long-term neurodegenerative process after a single TBI may reveal important targets for treatment with emerging anti-tau and anti-amyloid therapies.
The study was funded by the U.S. National Institutes of Health.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.